From our results, we concluded that of the potential biomarkers under study, CXCL10, CXCL9, and neopterin are the most fit for determining the level of spinal cord inflammation, and thus the most fit for predicting disease progression in HAM/TSP patients. The gene discussed is CXCL10; the disease is tropical spastic paraparesis.